Navigation Links
Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance
Date:12/14/2007

New tool for planning proton treatments makes it possible to precisely

control how dose is distributed inside the patient's body

PALO ALTO, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) has received FDA 510(k) clearance for a new proton scanning dose algorithm that offers clinicians greater control over how proton beams are used to target tumors and other abnormalities. The new algorithm, which has been incorporated into Varian's Eclipse(TM) treatment planning software, makes it possible to plan for intensity modulated proton therapy by optimizing dose distributions in three dimensions in order to protect surrounding healthy tissues.

This proton scanning technique improves on current proton delivery methods that require a therapist to enter and exit the treatment room numerous times throughout a treatment to adjust physical compensators for processing proton beams. "With proton scanning and intensity-modulation, this cumbersome process can be completely eliminated," said Jeff Amacker, Varian's business manager for treatment planning products.

PROTON THERAPY

Proton therapy uses a particle accelerator to generate a beam of protons and deposit them accurately within tumors while sparing adjacent healthy tissues and organs. Unlike the more common photon radiotherapy, with beams that pass all the way through the patient's body, proton therapy beams can be designed to stop and distribute most of their radiation dose at the depth of the tumor. This makes it possible to improve certain cancer treatments by protecting more healthy tissue and thus reduce short- and long-term side effects in cases where surrounding healthy tissues are particularly sensitive to radiation. Radiation o
'/>"/>

SOURCE Varian Medical Systems
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Historic Agreement Reached to More Expertly and Efficiently Expand Proton Therapy Worldwide
2. Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
3. Loma Linda University to Dedicate Proton Treatment Center to Cancer Therapy Pioneer James M. Slater, M.D.
4. Purdue researchers develop technology to detect cancer by scanning surface veins
5. Algorithms to reanimate the heart
6. Carnegie Mellon algorithm identifies top 100 blogs for news
7. Cranberry Could Juice Up Ovarian Cancer Treatment
8. New Ovarian Cancer Drug Trial Under Way
9. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
10. Pelvic Exams Can Help Spot Ovarian Cancer
11. Study fuels debate over whether exercise and body size influence ovarian cancer risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Conseco, Inc. (NYSE:,CNO) announced that Todd M. Hacker is ... president and treasurer. He will report to Ed,Bonach, Conseco,s ... Conseco from YRC Worldwide, where he was vice,president and ... From 2005-2006, he was senior vice president, finance and,administration, ...
... MCKINNEY, Texas, Jan. 8 Torchmark Corporation,(NYSE: TMK ... market,closes on Wednesday, February 6, 2008. In conjunction with ... listen to a,conference call that will be broadcast live ... a.m. Eastern. At that time a copy of the,Company,s ...
... HGR ) announced today that it plans to report ... on Monday, February 11,2008., The Company plans to issue ... 31, 2007 on Monday, February 11, 2008, after the,close of ... 9:00,a.m., EST, on Tuesday, February 12, 2008. Those wishing to ...
... LAKES, N.J., Jan. 8 Medco Health,Solutions, Inc. (NYSE: ... Jr. today,reiterated the company,s positive outlook for 2008 at ... The company reiterated its guidance for 2008 GAAP diluted ... assets that,existed when Medco became a publicly traded company, ...
... of developing breast cancer among people who carry the BRCA1 ... January 9/16 issue of JAMA. , BRCA1 and BRCA2 are ... magnitude of the risk of breast cancer in BRCA1 and ... options. The risk of breast cancer in BRCA1 and ...
... likely to undergo heart, liver and kidney transplantation , , TUESDAY, ... and rural areas are less likely to get organ transplants ... study found. , The study of almost 175,000 potential transplant ... percent to 15 percent less likely to be wait-listed and ...
Cached Medicine News:Health News:Torchmark Corporation Announces Fourth Quarter 2007 Earnings Release and Conference Call 2Health News:Hanger Orthopedic Group, Inc. Announces 2007 Year-End Earnings Release Conference Call 2Health News:Medco CEO Reiterates Guidance, Positive Outlook for 2008 2Health News:Breast cancer risk varies significantly among BRCA1 and BRCA2 carriers 2Health News:Rural Residents Get Fewer Organ Transplants: Study 2Health News:Rural Residents Get Fewer Organ Transplants: Study 3
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ... IBD biology, human genetics, genomic technology, and drug ...
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ... clinical and aesthetic dermatology practitioners in the 21 st ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, ... and technologies must be able to protect ... (IP). (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ... nature of the Medical Device Industry, it ... industry sectors of cases involving IP infringement. ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: